Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alagebrium in Diastolic Heart Failure
NCT00662116Phase 2Terminated
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Mar 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alagebrium in heart failure with preserved ejection fraction (HFpEF), sponsored by Synvista Therapeutics, Inc. Primary endpoint: 6 Minute Walk Test at 24 weeks. Started Mar 2008; status: terminated.
02
Drugs
alagebrium
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00662116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662116.